JP2010535811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535811A5 JP2010535811A5 JP2010520313A JP2010520313A JP2010535811A5 JP 2010535811 A5 JP2010535811 A5 JP 2010535811A5 JP 2010520313 A JP2010520313 A JP 2010520313A JP 2010520313 A JP2010520313 A JP 2010520313A JP 2010535811 A5 JP2010535811 A5 JP 2010535811A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- cancer
- agent
- composition
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001225 therapeutic effect Effects 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 41
- 239000002246 antineoplastic agent Substances 0.000 claims description 40
- 231100000765 toxin Toxicity 0.000 claims description 36
- 239000003053 toxin Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims description 17
- 239000008393 encapsulating agent Substances 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 101710164760 Chlorotoxin Proteins 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229960005534 chlorotoxin Drugs 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- -1 Azacitisine Chemical compound 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 230000002280 anti-androgenic effect Effects 0.000 claims description 5
- 230000003388 anti-hormonal effect Effects 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 239000000051 antiandrogen Substances 0.000 claims description 5
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 239000003886 aromatase inhibitor Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000000367 immunologic factor Substances 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 239000000649 purine antagonist Substances 0.000 claims description 5
- 239000003790 pyrimidine antagonist Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- 241000239226 Scorpiones Species 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- 230000006800 cellular catabolic process Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 239000012444 intercalating antibiotic Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 230000000394 mitotic effect Effects 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 3
- 231100000617 superantigen Toxicity 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 2
- 102000015790 Asparaginase Human genes 0.000 claims description 2
- 108010024976 Asparaginase Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
- 108010069236 Goserelin Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 108010000817 Leuprolide Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 101710183280 Topoisomerase Proteins 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001097 amifostine Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229960003272 asparaginase Drugs 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960002436 cladribine Drugs 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 229910052732 germanium Inorganic materials 0.000 claims description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002913 goserelin Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
- 229960004338 leuprorelin Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- 229960000350 mitotane Drugs 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000010132 spinal cord glioma Diseases 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 201000005565 spinal meningioma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- 239000011135 tin Substances 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 21
- 229940123237 Taxane Drugs 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Description
æ¬çºæã®ãããããã³ä»ã®ç®çãå©ç¹ããã³ç¹åŸŽã¯ã以äžã®å¥œãŸããå®æœåœ¢æ
ã®è©³çŽ°ãªèª¬æãèªãã°ãåœæ¥è
ã«æããã«ãªãã
æ¬çºæã®å¥œãŸããå®æœåœ¢æ ã§ã¯ãäŸãã°ä»¥äžãæäŸãããïŒ
ïŒé ç®ïŒïŒ
å°ãªããšãïŒã€ã®æ²»çéšåãšäŒåããå°ãªããšãïŒã€ã®æ¯çŽ éšåãå«ãçµåäœã§ãã£ãŠãããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãã©ã°ã¡ã³ããããã¯ãã®èªå°äœãå«ããçµåäœã
ïŒé ç®ïŒïŒ
åèšçµåäœã¯ãæ£åžžçŽ°èãããéžæçã«ãããã¯ç¹ç°çã«ç现èãæšçã«ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšçµåäœã¯ã现èã®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãåãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ²»çéšåã¯ãæçå€ãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæçå€ã¯ãç现èã«å¯ŸããŠäžååãªéžææ§ïŒç¹ç°æ§ã瀺ãæçå€ïŒç现èã«ããäžååãªåã蟌ã¿ã瀺ãæçå€ïŒç现èã«ãããŠäžååãªä¿æã瀺ãæçå€ïŒäžååãªæ°Žæº¶è§£æ§ã瀺ãæçå€ïŒç现èã«ãããŠæ©æäžæŽ»æ§åãåããæçå€ïŒç现èã«ãããŠæãªããã掻æ§åãåããæçå€ïŒåŸ¹åºçãªçŽ°èã«ããå解ãåããæçå€ïŒããã³è¬ç©èæ§ãšé¢é£ããæçå€ãããªã矀ã®ã¡ã³ããŒã§ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ²»çéšåã¯ãæŸå°æ§åäœäœãé µçŽ ããããã©ãã°æŽ»æ§åé µçŽ ãæŸå°ç·å¢æå€ãå¹²æžïŒ²ïŒ®ïŒ¡ãã¹ãŒããŒæåãæè¡ç®¡æ°çå€ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ã®ã¡ã³ããŒã§ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ãæšèãšäŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšæšèã¯ãæŸå°æ§æšèãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
æå¹éã®ãé ç®ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãïŒã€ã®çµåäœããŸãã¯ãã®ççåŠçã«èš±å®¹å¯èœãªå¡©ãããã³å°ãªããšãïŒçš®ã®è¬åŠçã«å容å¯èœãªãã£ãªã¢ãå«ããè¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
ååŠçæ³å€ãããã«å«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
ç现èã«å¯Ÿããæ²»çéšåã®ç¹ç°æ§ãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ç现èã«ããæ²»çéšåã®çŽ°èåã蟌ã¿ãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ç现èã«ããæ²»çéšåã®çŽ°èä¿æãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåããããé ç®ïŒïŒãïŒïŒãŸãã¯ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšç现èã¯ãåèšæ²»çå€ã«å¯ŸããŠèæ§ã§ãããé ç®ïŒïŒãïŒïŒãŸãã¯ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
çæ£è ãåŠçœ®ããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ãæå¹éã®ãé ç®ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœã該æ£è ã«æäžããå·¥çšãå å«ãããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã®æäžã¯ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã®ç¹ç°çæšçåãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããåã蟌ã¿ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããä¿æãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããå°ãªããããã¯é節床ãäœããæãŸãããªãå¯äœçšïŒãªãã³ã«å®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžãã匱ã现èå解ãã®ãã¡ã®ïŒã€ä»¥äžãçãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšç现èã¯ãåèšæ²»çéšåã«å¯ŸããŠèæ§ã®ç现èãå«ããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã®æäžã¯ãçµå£æäžãéçµå£æäžããããã¯çµè žæäžã«ãã£ãŠè¡ããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ååŠçæ³å€ãåèšæ£è ã«æäžããå·¥çšãããã«å å«ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ã®æäžã®åã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ã®æäžã®åŸã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ãšåæã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšååŠçæ³å€ã¯ãïœïŒ²ïŒ®ïŒ¡ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ããéžæããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšååŠçæ³å€ã¯ããã·ã¹ãã©ãã³ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ããã¯ãªã¿ãã»ã«ããã¢ãŸãããããããã«ã³ããã«ãªããŠã©ã·ã«ããã³ã¯ãªã¹ãã³ããã³ãã©ã¹ãã³ãããã«ã«ããžã³ããã«ã«ããžã³ãã¢ã«ãã¬ã¿ãã³ãã¡ããã¬ããµãŒããã¡ã«ã«ããããªã³ãããªã°ã¢ãã³ããªã³é žãã«ãã©ãã³ãã¯ã©ããªãã³ããã³ãã¹ã¿ãã³ãã·ã¿ã©ãã³ãã¢ã¶ã·ããžã³ïŒïœïœïœïœïœïœïœïœïœïœïœ ïŒããšããã·ãããããã·ããã€ãªããã«ã³ããã»ã¿ãã»ã«ããããœã«ãã·ã³ãããŠãã«ãã·ã³ããã¯ãããã€ã·ã³ãã€ãã«ãã·ã³ãããªã«ãã€ã·ã³ããã€ããã€ã·ã³ããã¬ãªãã€ã·ã³ãã¿ã¢ãã·ãã§ã³ããã«ã¿ããããã€ãããªãããŽã»ã¬ãªã³ãã¢ããã°ã«ãããããã¢ãã¹ãããŸãŒã«ãã¢ã ãµã¯ãªã³ãã¢ã¹ãã©ã®ããŒãŒãããããµã³ããã³ãããã¿ã³ãããã³ã¢ããã¹ãã³ãããªã矀ããéžæããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ£è ã¯ãèºçã骚çãèèçãèµèçãç®èçãé é žéšçãç®èé»è²è «ãããã¯çŒçå é»è²è «ãåå®®çãåµå·£çãçŽè žçãèéé åã®çãèçãçµè žçãä¹³çãåå®®çãæ§åšãŸãã¯çæ®åšå®ã®çè «ãããžãã³ç ãé£éçãå°è žã®çãå åæ³ç³»ã®çãç²ç¶è ºã®çãå¯ç²ç¶è ºã®çãå¯è ã®çãè»çµç¹ã®èè «ãå°¿éã®çãæ ¢æ§çœè¡ç ãããã¯æ¥æ§çœè¡ç ããªã³ãçæ§ãªã³ãè «ãèè±ã®çãè èã®çãè 现èçãäžæ¢ç¥çµç³»ïŒïŒ£ïŒ®ïŒ³ïŒã®æ°çç©ãç¥çµå€èèçãèé«è «çãç¥çµè è «ãé«èè «ãããã³äžåäœè ºè «ãããªã矀ã®ã¡ã³ããŒã§ããçã§ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ£è ã«ãããçã®ååšãæ€åºããå·¥çšãããã«å å«ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
çŽïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ã«å ±æçµåçã«é£çµãããæ¯çŽ éšåãå«ããçµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ãã¯ããããã·ã³éšåã§ãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ããµãœãªã¯ããããã·ã³ãšå°ãªããšãïŒïŒïŒ ã¢ããé žåäžæ§ãå ±æãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšã¯ããããã·ã³éšåã¯ããµãœãªã¯ããããã·ã³ã®ãã©ã°ã¡ã³ããå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãã¢ã³ãã»ã³ã¹è¬å€ãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãã¢ã³ãã»ã³ã¹è¬å€ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãã¢ã³ãã»ã³ã¹è¬å€ãééãããã¯ã¿ãŒãšããŠäœçšãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ãã³ã¢ããã³è¡šé¢ãæããç²åãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ¯çŽ éšåã¯ãåèšç²åã®è¡šé¢ã«çµåäœåããããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç²åã®æå°å¯žæ³ã¯ãçŽïŒÎŒïœæªæºã§ãããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç²åã®æå°å¯žæ³ã¯ãçŽïŒïŒïŒïœïœæªæºã§ãããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšã³ã¢ã¯ãç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªã¯ãã¢ã«ãããŠã ãã³ãã«ããã€ã³ãžãŠã ãéãé ãã²ã«ãããŠã ããã³ã¬ã³ãããã±ã«ãã¹ãºããã¿ã³ããã©ãžãŠã ãçœéãã»ã¬ã³ãã±ã€çŽ ãéãããã³äºéãããªã矀ããéžæãããååãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ããªããœãŒã ãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
以äžïŒ
é ç®ïŒâïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœïŒããã³
被å å€ã
ãå«ããè¬åŠççµæç©ã§ãã£ãŠãããã§è©²çµåäœã¯ã該被å å€å ã«éããããããŠãããè¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšè¢«å å€ã¯ããªããœãŒã ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšãªããœãŒã èå ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ²»çéšåã¯ãïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãåèšè¢«å å€ã«ãã£ãŠéãããããããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
æ¬çºæã®å¥œãŸããå®æœåœ¢æ ã§ã¯ãäŸãã°ä»¥äžãæäŸãããïŒ
ïŒé ç®ïŒïŒ
å°ãªããšãïŒã€ã®æ²»çéšåãšäŒåããå°ãªããšãïŒã€ã®æ¯çŽ éšåãå«ãçµåäœã§ãã£ãŠãããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãã©ã°ã¡ã³ããããã¯ãã®èªå°äœãå«ããçµåäœã
ïŒé ç®ïŒïŒ
åèšçµåäœã¯ãæ£åžžçŽ°èãããéžæçã«ãããã¯ç¹ç°çã«ç现èãæšçã«ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšçµåäœã¯ã现èã®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãåãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ²»çéšåã¯ãæçå€ãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæçå€ã¯ãç现èã«å¯ŸããŠäžååãªéžææ§ïŒç¹ç°æ§ã瀺ãæçå€ïŒç现èã«ããäžååãªåã蟌ã¿ã瀺ãæçå€ïŒç现èã«ãããŠäžååãªä¿æã瀺ãæçå€ïŒäžååãªæ°Žæº¶è§£æ§ã瀺ãæçå€ïŒç现èã«ãããŠæ©æäžæŽ»æ§åãåããæçå€ïŒç现èã«ãããŠæãªããã掻æ§åãåããæçå€ïŒåŸ¹åºçãªçŽ°èã«ããå解ãåããæçå€ïŒããã³è¬ç©èæ§ãšé¢é£ããæçå€ãããªã矀ã®ã¡ã³ããŒã§ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒ
åèšæ²»çéšåã¯ãæŸå°æ§åäœäœãé µçŽ ããããã©ãã°æŽ»æ§åé µçŽ ãæŸå°ç·å¢æå€ãå¹²æžïŒ²ïŒ®ïŒ¡ãã¹ãŒããŒæåãæè¡ç®¡æ°çå€ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ã®ã¡ã³ããŒã§ãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ãæšèãšäŒåãããŠãããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšæšèã¯ãæŸå°æ§æšèãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
æå¹éã®ãé ç®ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãïŒã€ã®çµåäœããŸãã¯ãã®ççåŠçã«èš±å®¹å¯èœãªå¡©ãããã³å°ãªããšãïŒçš®ã®è¬åŠçã«å容å¯èœãªãã£ãªã¢ãå«ããè¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
ååŠçæ³å€ãããã«å«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
ç现èã«å¯Ÿããæ²»çéšåã®ç¹ç°æ§ãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ç现èã«ããæ²»çéšåã®çŽ°èåã蟌ã¿ãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ç现èã«ããæ²»çéšåã®çŽ°èä¿æãå¢å€§ãããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ã該治çéšåããæ¯çŽ éšåã«äŒåãããŠãçµåäœã圢æããå·¥çšãå å«ããããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãµããŠããããããã¯ãã®èªå°äœãå«ããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåããããé ç®ïŒïŒãïŒïŒãŸãã¯ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšç现èã¯ãåèšæ²»çå€ã«å¯ŸããŠèæ§ã§ãããé ç®ïŒïŒãïŒïŒãŸãã¯ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
çæ£è ãåŠçœ®ããããã®æ¹æ³ã§ãã£ãŠã該æ¹æ³ã¯ãæå¹éã®ãé ç®ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœã該æ£è ã«æäžããå·¥çšãå å«ãããæ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã®æäžã¯ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã®ç¹ç°çæšçåãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããåã蟌ã¿ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããä¿æãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããå°ãªããããã¯é節床ãäœããæãŸãããªãå¯äœçšïŒãªãã³ã«å®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžãã匱ã现èå解ãã®ãã¡ã®ïŒã€ä»¥äžãçãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšç现èã¯ãåèšæ²»çéšåã«å¯ŸããŠèæ§ã®ç现èãå«ããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã®æäžã¯ãçµå£æäžãéçµå£æäžããããã¯çµè žæäžã«ãã£ãŠè¡ããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
ååŠçæ³å€ãåèšæ£è ã«æäžããå·¥çšãããã«å å«ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ã®æäžã®åã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ã®æäžã®åŸã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšååŠçæ³å€ãšåæã«æäžããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšååŠçæ³å€ã¯ãïœïŒ²ïŒ®ïŒ¡ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ããéžæããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšååŠçæ³å€ã¯ããã·ã¹ãã©ãã³ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ããã¯ãªã¿ãã»ã«ããã¢ãŸãããããããã«ã³ããã«ãªããŠã©ã·ã«ããã³ã¯ãªã¹ãã³ããã³ãã©ã¹ãã³ãããã«ã«ããžã³ããã«ã«ããžã³ãã¢ã«ãã¬ã¿ãã³ãã¡ããã¬ããµãŒããã¡ã«ã«ããããªã³ãããªã°ã¢ãã³ããªã³é žãã«ãã©ãã³ãã¯ã©ããªãã³ããã³ãã¹ã¿ãã³ãã·ã¿ã©ãã³ãã¢ã¶ã·ããžã³ïŒïœïœïœïœïœïœïœïœïœïœïœ ïŒããšããã·ãããããã·ããã€ãªããã«ã³ããã»ã¿ãã»ã«ããããœã«ãã·ã³ãããŠãã«ãã·ã³ããã¯ãããã€ã·ã³ãã€ãã«ãã·ã³ãããªã«ãã€ã·ã³ããã€ããã€ã·ã³ããã¬ãªãã€ã·ã³ãã¿ã¢ãã·ãã§ã³ããã«ã¿ããããã€ãããªãããŽã»ã¬ãªã³ãã¢ããã°ã«ãããããã¢ãã¹ãããŸãŒã«ãã¢ã ãµã¯ãªã³ãã¢ã¹ãã©ã®ããŒãŒãããããµã³ããã³ãããã¿ã³ãããã³ã¢ããã¹ãã³ãããªã矀ããéžæããããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ£è ã¯ãèºçã骚çãèèçãèµèçãç®èçãé é žéšçãç®èé»è²è «ãããã¯çŒçå é»è²è «ãåå®®çãåµå·£çãçŽè žçãèéé åã®çãèçãçµè žçãä¹³çãåå®®çãæ§åšãŸãã¯çæ®åšå®ã®çè «ãããžãã³ç ãé£éçãå°è žã®çãå åæ³ç³»ã®çãç²ç¶è ºã®çãå¯ç²ç¶è ºã®çãå¯è ã®çãè»çµç¹ã®èè «ãå°¿éã®çãæ ¢æ§çœè¡ç ãããã¯æ¥æ§çœè¡ç ããªã³ãçæ§ãªã³ãè «ãèè±ã®çãè èã®çãè 现èçãäžæ¢ç¥çµç³»ïŒïŒ£ïŒ®ïŒ³ïŒã®æ°çç©ãç¥çµå€èèçãèé«è «çãç¥çµè è «ãé«èè «ãããã³äžåäœè ºè «ãããªã矀ã®ã¡ã³ããŒã§ããçã§ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
åèšæ£è ã«ãããçã®ååšãæ€åºããå·¥çšãããã«å å«ãããé ç®ïŒïŒã«èšèŒã®æ¹æ³ã
ïŒé ç®ïŒïŒïŒ
çŽïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ã«å ±æçµåçã«é£çµãããæ¯çŽ éšåãå«ããçµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ãã¯ããããã·ã³éšåã§ãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ¯çŽ éšåã¯ããµãœãªã¯ããããã·ã³ãšå°ãªããšãïŒïŒïŒ ã¢ããé žåäžæ§ãå ±æãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšã¯ããããã·ã³éšåã¯ããµãœãªã¯ããããã·ã³ã®ãã©ã°ã¡ã³ããå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãã¢ã³ãã»ã³ã¹è¬å€ãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãã¢ã³ãã»ã³ã¹è¬å€ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãã¢ã³ãã»ã³ã¹è¬å€ãééãããã¯ã¿ãŒãšããŠäœçšãããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããé ç®ïŒïŒã«èšèŒã®çµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ãã³ã¢ããã³è¡šé¢ãæããç²åãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ¯çŽ éšåã¯ãåèšç²åã®è¡šé¢ã«çµåäœåããããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç²åã®æå°å¯žæ³ã¯ãçŽïŒÎŒïœæªæºã§ãããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç²åã®æå°å¯žæ³ã¯ãçŽïŒïŒïŒïœïœæªæºã§ãããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšã³ã¢ã¯ãç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªã¯ãã¢ã«ãããŠã ãã³ãã«ããã€ã³ãžãŠã ãéãé ãã²ã«ãããŠã ããã³ã¬ã³ãããã±ã«ãã¹ãºããã¿ã³ããã©ãžãŠã ãçœéãã»ã¬ã³ãã±ã€çŽ ãéãããã³äºéãããªã矀ããéžæãããååãå«ããé ç®ïŒïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ããªããœãŒã ãå«ããé ç®ïŒã«èšèŒã®çµåäœã
ïŒé ç®ïŒïŒïŒ
以äžïŒ
é ç®ïŒâïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœïŒããã³
被å å€ã
ãå«ããè¬åŠççµæç©ã§ãã£ãŠãããã§è©²çµåäœã¯ã該被å å€å ã«éããããããŠãããè¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšè¢«å å€ã¯ããªããœãŒã ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšçµåäœã¯ãåèšãªããœãŒã èå ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ²»çéšåã¯ãïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãã³ãŒããããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãåèšè¢«å å€ã«ãã£ãŠéãããããããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
ïŒé ç®ïŒïŒïŒ
åèšæ žé žè¬å€ã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸãããé ç®ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
Claims (57)
- å°ãªããšãïŒã€ã®æ²»çéšåãšäŒåããå°ãªããšãïŒã€ã®æ¯çŽ éšåãå«ãçµåäœã§ãã£ãŠãããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãã©ã°ã¡ã³ããããã¯ãã®èªå°äœãå«ããçµåäœã
- åèšçµåäœã¯ãæ£åžžçŽ°èãããéžæçã«ãããã¯ç¹ç°çã«ç现èãæšçã«ãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšçµåäœã¯ã现èã®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãåãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåãããŠãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåãããŠãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåãããŠãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ²»çéšåã¯ãæçå€ãå«ããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæçå€ã¯ãç现èã«å¯ŸããŠäžååãªéžææ§ïŒç¹ç°æ§ã瀺ãæçå€ïŒç现èã«ããäžååãªåã蟌ã¿ã瀺ãæçå€ïŒç现èã«ãããŠäžååãªä¿æã瀺ãæçå€ïŒäžååãªæ°Žæº¶è§£æ§ã瀺ãæçå€ïŒç现èã«ãããŠæ©æäžæŽ»æ§åãåããæçå€ïŒç现èã«ãããŠæãªããã掻æ§åãåããæçå€ïŒåŸ¹åºçãªçŽ°èã«ããå解ãåããæçå€ïŒããã³è¬ç©èæ§ãšé¢é£ããæçå€ãããªã矀ã®ã¡ã³ããŒã§ãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ²»çéšåã¯ãæŸå°æ§åäœäœãé µçŽ ããããã©ãã°æŽ»æ§åé µçŽ ãæŸå°ç·å¢æå€ãå¹²æžïŒ²ïŒ®ïŒ¡ãã¹ãŒããŒæåãæè¡ç®¡æ°çå€ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ã®ã¡ã³ããŒã§ãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåã¯ãæšèãšäŒåãããŠãããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšæšèã¯ãæŸå°æ§æšèãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- çæ£è ãåŠçœ®ããããã®çµæç©ã§ãã£ãŠã該çµæç©ã¯ãæå¹éã®ãè«æ±é ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœãŸãã¯ãã®ççåŠçã«èš±å®¹å¯èœãªå¡©ãããã³å°ãªããšãïŒçš®ã®è¬åŠçã«å容å¯èœãªãã£ãªã¢ãå«ããçµæç©ã
- åèšçµåäœã®æäžã¯ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã®ç¹ç°çæšçåãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããåã蟌ã¿ãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããé«ãç现èã«ããä¿æãå®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžããå°ãªããããã¯é節床ãäœããæãŸãããªãå¯äœçšïŒãªãã³ã«å®è³ªçã«åäžã®æ¡ä»¶äžã§ã®åèšæ²»çéšåã®æäžãã匱ã现èå解ãã®ãã¡ã®ïŒã€ä»¥äžãçãããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšç现èã¯ãåèšæ²»çéšåã«å¯ŸããŠèæ§ã®ç现èãå«ããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- çµå£æäžãéçµå£æäžããããã¯çµè žæäžã®ããã«åŠæ¹ããããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- ååŠçæ³å€ãšçµã¿åãããŠäœ¿çšããããã®ãè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšäœ¿çšã¯ãåèšååŠçæ³å€ã®åãåŸãŸãã¯åæã§ãããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšååŠçæ³å€ã¯ãïœïŒ²ïŒ®ïŒ¡ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ããéžæããããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšååŠçæ³å€ã¯ããã·ã¹ãã©ãã³ãã²ã ã·ã¿ãã³ãããããã·ãŠã¬ã¢ããã¯ãªã¿ãã»ã«ããã¢ãŸãããããããã«ã³ããã«ãªããŠã©ã·ã«ããã³ã¯ãªã¹ãã³ããã³ãã©ã¹ãã³ãããã«ã«ããžã³ããã«ã«ããžã³ãã¢ã«ãã¬ã¿ãã³ãã¡ããã¬ããµãŒããã¡ã«ã«ããããªã³ãããªã°ã¢ãã³ããªã³é žãã«ãã©ãã³ãã¯ã©ããªãã³ããã³ãã¹ã¿ãã³ãã·ã¿ã©ãã³ãã¢ã¶ã·ããžã³ïŒïœïœïœïœïœïœïœïœïœïœïœ ïŒããšããã·ãããããã·ããã€ãªããã«ã³ããã»ã¿ãã»ã«ããããœã«ãã·ã³ãããŠãã«ãã·ã³ããã¯ãããã€ã·ã³ãã€ãã«ãã·ã³ãããªã«ãã€ã·ã³ããã€ããã€ã·ã³ããã¬ãªãã€ã·ã³ãã¿ã¢ãã·ãã§ã³ããã«ã¿ããããã€ãããªãããŽã»ã¬ãªã³ãã¢ããã°ã«ãããããã¢ãã¹ãããŸãŒã«ãã¢ã ãµã¯ãªã³ãã¢ã¹ãã©ã®ããŒãŒãããããµã³ããã³ãããã¿ã³ãããã³ã¢ããã¹ãã³ãããªã矀ããéžæããããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- èºçã骚çãèèçãèµèçãç®èçãé é žéšçãç®èé»è²è «ãããã¯çŒçå é»è²è «ãåå®®çãåµå·£çãçŽè žçãèéé åã®çãèçãçµè žçãä¹³çãæ§åšãŸãã¯çæ®åšå®ã®çè «ãããžãã³ç ãé£éçãå°è žã®çãå åæ³ç³»ã®çãç²ç¶è ºã®çãå¯ç²ç¶è ºã®çãå¯è ã®çãè»çµç¹ã®èè «ãå°¿éã®çãæ ¢æ§çœè¡ç ãããã¯æ¥æ§çœè¡ç ããªã³ãçæ§ãªã³ãè «ãèè±ã®çãè èã®çãè 现èçãäžæ¢ç¥çµç³»ïŒïŒ£ïŒ®ïŒ³ïŒã®æ°çç©ãç¥çµå€èèçãèé«è «çãç¥çµè è «ãé«èè «ãããã³äžåäœè ºè «ãããªã矀ã®ã¡ã³ããŒã§ããçã®åŠçœ®ã«äœ¿çšããããã®ãè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- çŽïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ã«å ±æçµåçã«é£çµãããæ¯çŽ éšåãå«ããçµæç©ã
- åèšæ¯çŽ éšåã¯ãã¯ããããã·ã³éšåã§ãããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšæ¯çŽ éšåã¯ããµãœãªã¯ããããã·ã³ãšå°ãªããšãïŒïŒïŒ ã¢ããé žåäžæ§ãå ±æãããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšã¯ããããã·ã³éšåã¯ããµãœãªã¯ããããã·ã³ã®ãã©ã°ã¡ã³ããå«ããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšæ žé žè¬å€ã¯ãã¢ã³ãã»ã³ã¹è¬å€ãå«ãããŸãã¯ã³ãŒããããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãã¢ã³ãã»ã³ã¹è¬å€ãééãããã¯ã¿ãŒãšããŠäœçšãããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ãããŸãã¯ã³ãŒããããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããè«æ±é ïŒïŒã«èšèŒã®çµæç©ã
- åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ãã³ã¢ããã³è¡šé¢ãæããç²åãå«ããè«æ±é ïŒã«èšèŒã®çµåäœã
- åèšå°ãªããšãïŒã€ã®æ¯çŽ éšåã¯ãåèšç²åã®è¡šé¢ã«çµåäœåããããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšã³ã¢ã¯ãç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšç£æ°å ±é³ŽæŽ»æ§ãæããç©è³ªã¯ãã¢ã«ãããŠã ãã³ãã«ããã€ã³ãžãŠã ãéãé ãã²ã«ãããŠã ããã³ã¬ã³ãããã±ã«ãã¹ãºããã¿ã³ããã©ãžãŠã ãçœéãã»ã¬ã³ãã±ã€çŽ ãéãããã³äºéãããªã矀ããéžæãããååãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšå°ãªããšãïŒã€ã®æ²»çéšåã¯ããªããœãŒã ãå«ããè«æ±é ïŒã«èšèŒã®çµåäœã
- 以äžïŒ
è«æ±é ïŒãïŒïŒã®ããããïŒé ã«èšèŒã®çµåäœïŒããã³
被å å€ã
ãå«ããè¬åŠççµæç©ã§ãã£ãŠãããã§è©²çµåäœã¯ã該被å å€å ã«éããããããŠãããè¬åŠççµæç©ã - åèšçµåäœã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšè¢«å å€ã¯ããªããœãŒã ãå«ããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšçµåäœã¯ãåèšãªããœãŒã èå ã«å°ãªããšãéšåçã«åã蟌ãŸããŠãããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ²»çéšåã¯ãïŒãïŒïŒïŒïŒãã¯ã¬ãªããé·ã®éã®æ žé žè¬å€ãå«ããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãå«ããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ žé žè¬å€ã¯ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãã³ãŒããããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ žé žè¬å€ã¯ã现èã«å°å ¥ããããšãã«ãé»å®³æ§ïŒ²ïŒ®ïŒ¡ãééãããã¯ã¿ãŒãå«ããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ žé žè¬å€ã¯ãåèšè¢«å å€ã«ãã£ãŠéãããããããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- åèšæ žé žè¬å€ã¯ãåèšè¢«å å€å ã«å°ãªããšãéšåçã«åã蟌ãŸãããè«æ±é ïŒïŒã«èšèŒã®è¬åŠççµæç©ã
- å°ãªããšãïŒã€ã®æ²»çéšåãšäŒåããå°ãªããšãïŒã€ã®æ¯çŽ éšåãå«ãçµåäœã§ãã£ãŠãããã§è©²æ¯çŽ éšåã¯ãã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãã©ã°ã¡ã³ãããŸãã¯é åçªå·ïŒã«å°ãªããšãïŒïŒïŒ ã®é ååäžæ§ãæãããã®èªå°äœãå«ããçµåäœã
- åèšã¯ããããã·ã³ããã®çç©åŠçã«æŽ»æ§ãªãã©ã°ã¡ã³ããããã¯ãã®èªå°äœã¯ãã¯ããããã·ã³ã®æŽ»æ§ãšé¢é£ããå°ãªããšãïŒåé£ç¶ããã¢ããé žæ®åºãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåã¯ãã¯ããããã·ã³ã®æŽ»æ§ãšé¢é£ããå°ãªããšãïŒåé£ç¶ããã¢ããé žæ®åºãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãå ±æçµåçã«äŒåãããŠãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ãçŽæ¥çã«å ±æçµåçã«äŒåãããŠãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåããã³æ²»çéšåã¯ããªã³ã«ãŒãä»ããŠå ±æçµåçã«äŒåãããŠãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ²»çéšåã¯ãæçå€ãå«ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæçå€ã¯ãç现èã«å¯ŸããŠäžååãªéžææ§ïŒç¹ç°æ§ã瀺ãæçå€ïŒç现èã«ããäžååãªåã蟌ã¿ã瀺ãæçå€ïŒç现èã«ãããŠäžååãªä¿æã瀺ãæçå€ïŒäžååãªæ°Žæº¶è§£æ§ã瀺ãæçå€ïŒç现èã«ãããŠæ©æäžæŽ»æ§åãåããæçå€ïŒç现èã«ãããŠæãªããã掻æ§åãåããæçå€ïŒåŸ¹åºçãªçŽ°èã«ããå解ãåããæçå€ïŒããã³è¬ç©èæ§ãšé¢é£ããæçå€ãããªã矀ã®ã¡ã³ããŒã§ãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæçå€ã¯ãäžååãªæ°Žæº¶è§£æ§ã瀺ããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæçå€ãã¿ããµã³ã§ãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšã¿ããµã³ãããã¯ãªã¿ãã»ã«ããã»ã¿ãã»ã«ããã³ãããã®çµã¿åãããããªã矀ããéžæããããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšã¿ããµã³ãããã¯ãªã¿ãã»ã«ã§ãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ²»çéšåã¯ãæŸå°æ§åäœäœãé µçŽ ããããã©ãã°æŽ»æ§åé µçŽ ãæŸå°ç·å¢æå€ãå¹²æžïŒ²ïŒ®ïŒ¡ãã¹ãŒããŒæåãæè¡ç®¡æ°çå€ãã¢ã«ãã«åå€ãããªã³ã¢ã³ã¿ãŽãã¹ããããªããžã³ã¢ã³ã¿ãŽãã¹ããæ€ç©ã¢ã«ã«ãã€ããã€ã³ã¿ãŒã«ã¬ãŒãæçç©è³ªãã¢ããã¿ãŒãŒã€ã³ããã¿ãŒã代è¬æ®æç©è³ªãæ糞åè£ã€ã³ããã¿ãŒãå¢æ®å åã€ã³ããã¿ãŒã现èåšæã€ã³ããã¿ãŒãé µçŽ ãããã€ãœã¡ã©ãŒãŒã€ã³ããã¿ãŒãçç©åŠçå¿çæ¹å€å åãæãã«ã¢ã³ããã³æã¢ã³ããã²ã³ãããªã矀ã®ã¡ã³ããŒã§ãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
- åèšæ¯çŽ éšåã¯ãæšèãšäŒåãããŠãããè«æ±é ïŒïŒã«èšèŒã®çµåäœã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95440907P | 2007-08-07 | 2007-08-07 | |
PCT/US2008/072524 WO2009021136A1 (en) | 2007-08-07 | 2008-08-07 | Chlorotoxins as drug carriers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010535811A JP2010535811A (ja) | 2010-11-25 |
JP2010535811A5 true JP2010535811A5 (ja) | 2011-09-22 |
Family
ID=40341745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010520313A Withdrawn JP2010535811A (ja) | 2007-08-07 | 2008-08-07 | è¬ç©ãã£ãªã¢ãšããŠã®ã¯ããããã·ã³ |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110091380A1 (ja) |
EP (1) | EP2173385A1 (ja) |
JP (1) | JP2010535811A (ja) |
AU (1) | AU2008285364A1 (ja) |
CA (1) | CA2696303A1 (ja) |
WO (1) | WO2009021136A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006020710D1 (de) | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
JP2011520914A (ja) | 2008-05-15 | 2011-07-21 | ãã©ã³ã¹ã¢ã¬ãã¥ã©ãŒïŒ ã€ã³ã³ãŒãã¬ã€ããã | è»¢ç§»è «çã®åŠçœ® |
EP2531206B1 (en) | 2010-02-04 | 2017-05-31 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
WO2011126010A1 (ja) * | 2010-04-06 | 2011-10-13 | äžè±ååŠæ ªåŒäŒç€Ÿ | ç现èéžæçèééæ§ããããããã³ãã®å©çš |
EP2569330B1 (en) | 2010-05-11 | 2016-09-28 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
WO2013003507A1 (en) | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
BR112015013515A2 (pt) | 2012-12-10 | 2017-11-14 | Hutchinson Fred Cancer Res | métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptÃdeos possuindo uma propriedade farmacológica |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
WO2018107134A1 (en) * | 2016-12-09 | 2018-06-14 | The Uab Research Foundation | Chimeric chlorotoxin receptors |
EP3681540A4 (en) | 2017-09-15 | 2021-05-19 | Eisai, Inc. | CHLOROTOXIN AGENT AND USES THEREOF |
CA3086040A1 (en) | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
AU2003237347B2 (en) * | 2002-05-31 | 2009-07-23 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
KR20070039593A (ko) * | 2004-07-21 | 2007-04-12 | ìëžë£©ì€, ìžìœí¬ë ìŽí°ë | ë¹ì²ì°ì ìŒë¡ ìœë©ë ìë¯žë žì°ì ìŽì©í ìí©ì± íŽëŠ¬í©í°ë |
DE602006020710D1 (de) * | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
-
2008
- 2008-08-07 WO PCT/US2008/072524 patent/WO2009021136A1/en active Application Filing
- 2008-08-07 JP JP2010520313A patent/JP2010535811A/ja not_active Withdrawn
- 2008-08-07 EP EP08797415A patent/EP2173385A1/en not_active Withdrawn
- 2008-08-07 CA CA2696303A patent/CA2696303A1/en not_active Abandoned
- 2008-08-07 US US12/672,069 patent/US20110091380A1/en not_active Abandoned
- 2008-08-07 AU AU2008285364A patent/AU2008285364A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010535811A5 (ja) | ||
JP6181265B2 (ja) | ã¯ããããã·ã³ããªããããããã³ã³ã³ãžã¥ã²ãŒããªãã³ã«ãã®äœ¿çš | |
TWI361689B (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
JP2013518905A5 (ja) | ||
AU2018250312B2 (en) | Bioorthogonal compositions | |
JP2011520914A5 (ja) | ||
JP2018536012A (ja) | çäœçŽäº€åçµæç© | |
US20210059942A1 (en) | Compositions and methods of treating therapy resistant cancer and uses thereof | |
WO2012106713A2 (en) | Targeted nanoparticle conjugates | |
JP7067802B2 (ja) | ã¢ãã¿ããŒïŒè¬ç©ã³ã³ãžã¥ã²ãŒãåã³ãã®çšé | |
CN110520161A (zh) | çšäºççéæ©æ§æ è®°åé¶åç觊ååšå¯æ¿æŽ»çç³çŒåç© | |
TW200812590A (en) | Methods for cancer therapy and stem cell modulation | |
JP2010535811A (ja) | è¬ç©ãã£ãªã¢ãšããŠã®ã¯ããããã·ã³ | |
JP2016106120A (ja) | çæ²»çã®ããã®ããªããµã³ãã³ãããŒã¹ãšãããªãŒããã¡ãžãŒé»å®³å€çæ³ | |
JP2018510154A (ja) | çã®æ°æ²»çæ³ | |
Malhi et al. | Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach | |
US20110152252A1 (en) | Shiga toxin b-subunit/chemotherapeutics conjugates | |
TW200836762A (en) | Polymeric short interfering RNA conjugates | |
EP2600844A2 (en) | Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof | |
US11286489B2 (en) | POSH inhibitor complex biomolecules and amphiphile micelles | |
TWI454280B (zh) | Pharmaceutical composition or combination | |
CN103108641B (zh) | Sdf-1ç»åæ§æ žé žåå ¶åšççæ²»çäžççšé | |
Dukes et al. | Delivery of Targeted Co (III)âDNA Inhibitors of Gli Proteins to Disrupt Hedgehog Signaling | |
EP3532086A1 (fr) | Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers | |
Alshaker et al. | PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel |